You are browsing articles on the topic of Electrophysiology Archives - CardioExchange

Avatar of Promporn

Assessing the MRI Safety of New Pacemakers and ICDs (8 Apr 2014)

Voices

Promporn Suksaranjit, M.D.

Promporn Suksaranjit provides an update on the safety of pacemakers and ICDs in an MRI environment.

Avatar of Arthur J. Moss, MD

Long-Term Follow-Up from MADIT-CRT: Guideline Implications (30 Mar 2014)

Voices

Arthur J. Moss, MD

Arthur J. Moss discusses his research group’s study of long-term survival for patients who received cardiac resynchronization therapy with a defibrillator in the MADIT-CRT trial.

Avatar of Larry Husten, PHD

MADIT-CRT Long-Term Follow-Up Shows Survival Benefit with CRT-D (30 Mar 2014)

News

MADIT-CRT was an influential trial that showed a reduction in heart failure complications — but not mortality — when cardiac resynchronization therapy (CRT) was added to an implantable defibrillator in patients with mild heart failure who also had left bundle-branch block (LBBB). Patients in the trial were followed for 2.4 years, raising questions about the long-term effects…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Edward

How Sure Can We Be About Optisure? (28 Mar 2014)

Voices

Edward J. Schloss, MD

Edward J. Schloss reflects on the release of the new Optisure family of ICD leads by St. Jude Medical, as well as the history of leads made by this company.

Avatar of Larry Husten, PHD

ACC.14 Preview: Renal Denervation, TAVR Comparisons, and More (24 Mar 2014)

News

The ACC begins this Saturday in Washington, DC. Here’s a preview of some of the most highly anticipated late-breaking clinical trials: On Saturday morning at the opening session the world will finally learn more about the failure of Symplicity HTN-3, the Medtronic trial of renal denervation. Until recently, renal denervation was thought to be an…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

AF Patients with Chronic Kidney Disease Also Benefit from Warfarin (4 Mar 2014)

News

Anticoagulation is a cornerstone of therapy for atrial fibrillation because it lowers the heightened risk for stroke in this population. People with chronic kidney disease are also at increased risk for stroke, but the benefits of anticoagulation are less clear in this group, and anticoagulation is used less often in AF patients who have CKD….

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Anna

Case: Palpitations in a Young Runner with Lamin A/C Deficiency (3 Mar 2014)

Cardiology Case Discussion

Anna Catino, MD and James Fang, MD

Anna Catino presents our latest case: A young, male, long-distance runner experiencing palpitations, who has lamin A/C deficiency and a family history of cardiac disease. How would you manage this patient?

Avatar of Larry Husten, PHD

FDA Approves New Catheter for Treatment of Atrial Fibrillation (25 Feb 2014)

News

The FDA has granted marketing approval for the Thermocool Smarttouch ablation catheter for use in patients with drug-resistant paroxysmal atrial fibrillation (AF), sustained monomorphic ischemic ventricular tachycardia, and type I atrial flutter. The device is manufactured by Biosense Webster, a Johnson & Johnson company. The device, according to the company, “is the first therapeutic catheter approved in…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Trial Offers Little Support for Early Use of Radiofrequency Ablation in Atrial Fibrillation (18 Feb 2014)

News

A new trial offers little support for early use of radiofrequency ablation (RFA) to treat atrial fibrillation (AF). Current guidelines state that RFA may be indicated in patients with symptomatic paroxysmal AF after antiarrhythmic drug therapy has failed. Although earlier hopes have been dashed that RFA would prove to be a cure for AF, some experts…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

FDA Once Again Rejects New Indication For Rivaroxaban (14 Feb 2014)

News

The third time wasn’t the charm. The FDA today turned turned down — for the third time — the supplemental New Drug Application (sNDA) for rivaroxaban (Xarelto, Johnson & Johnson) for use in acute coronary syndrome patients to reduce MI, stroke, or death. In addition, the FDA — for the second time — turned down the sNDA for rivaroxaban in…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.